Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BSY001 After Single/Multiple Doses.

A Two-Phase, Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BSY001 for Injection Following Single or Multiple Doses in Healthy Subjects.

A Two-Phase, Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BSY001 for Injection Following Single or Multiple Doses in Healthy Subjects

Study Overview

• Status: Recruiting
• Conditions: Smallpox; Monkeypox; Poxvirus Infection; Cowpox
• Intervention / Treatment: Drug: BSY001 for Injection (37.5mg); Drug: placebo-SAD; Drug: BSY001 for Injection (75 mg); Drug: BSY001 for Injection (150 mg); Drug: BSY001 for Injection (200 mg); Drug: BSY001 for Injection (300 mg); Drug: BSY001 for Injection; Drug: placebo-MAD

Detailed Description

This study is divided into two parts: a single-dose study (BSY001-A) and a multiple-dose study (BSY001-B). Subjects for BSY001-B will be enrolled only after all subjects participating in BSY001-A have completed the pharmacokinetic (PK) tests and safety follow-ups for all dose groups, and the corresponding PK parameters and preliminary safety results have been obtained.

BSY001-A: A single ascending dose study conducted in healthy subjects. The trial includes five dose groups: 37.5, 75, 150, 200, and 300 mg, starting from the low-dose group. A total of 46 subjects are planned for enrollment. For the 37.5 mg and 75 mg dose groups, 8 subjects will be enrolled in each group, with 6 receiving BSY001 for injection and 2 receiving placebo. For the 150 mg, 200 mg, and 300 mg dose groups, 10 subjects will be enrolled in each group, including 8 receiving BSY001 for injection and 2 receiving placebo. All subjects will receive a single administration of either BSY001 for injection or placebo. PK blood samples will be collected both prior to and after the initiation of dosing. Subjects who complete PK blood sampling and safety follow-ups may be discontinued from the study. Tolerability assessment will be performed on Day 4 for each dose group, and dosing of the next dose group may commence only after the Safety Monitoring Committee (SMC) confirms safety and tolerability.

BSY001-B: A randomized, double-blind, multiple-dose pharmacokinetic study conducted in healthy subjects. A total of 30 eligible subjects will be enrolled after screening, including 24 in the treatment group and 6 in the placebo group. Subjects will receive 200 mg of BSY001 for injection or placebo, administered once every 12 hours ± 10 minutes for 14 consecutive days. During hospitalization, subjects will be under centralized management by the study center, with blood sample collection and safety assessments performed as scheduled.

• Study Type: Interventional
• Enrollment (Estimated): 76
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Wei Wang; Phone Number: +86-010-60963099; Email: nvsiclinicaltrials@163.com

Study Locations

• China
  • Hangzhou, China
    • Recruiting
    • Shulan (Hangzhou) Hospital
    • Contact: Guiling Chen; Phone Number: +86-18343113983; Email: chenguiling707@126.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

1. Subjects voluntarily participate in the study, sign the informed consent form, and agree to comply with all study requirements;
2. Aged ≥ 18 years and ≤ 50 years (based on the date of signing the informed consent form), including both males and females;
3. Body Mass Index (BMI) between 19.0 and 30.0 kg/m² (19.0 and 30.0 kg/m² inclusive); for female subjects, body weight between 45.0 and 120.0 kg (45.0 kg inclusive and 120.0 kg exclusive); for male subjects, body weight between 50.0 and 120.0 kg (50.0 kg inclusive and 120.0 kg exclusive);
4. Subjects (including their partners) voluntarily adopt effective contraceptive measures from 1 month before screening to 6 months after the last administration of the study drug, and have no plans for childbearing, sperm donation, or egg donation within the next 6 months.

Exclusion Criteria:

1. Subjects with a known allergy to Tecovirimat drugs, any excipient ingredients in this product, or subjects with an allergic diathesis (allergic to ≥ 2 types of substances);
2. Subjects with clinically significant abnormal electrocardiogram (ECG) findings or QTc prolongation as determined by the investigator (e.g., QTc interval ≥ 450 ms in males and ≥ 470 ms in females, with QTc interval calculated using the Fridericia formula);
3. Subjects with a creatinine clearance rate (Cockcroft-Gault formula) < 90 mL/min;
4. Subjects with clinically significant abnormalities in physical examination, vital signs, laboratory tests, or other auxiliary examinations as determined by the investigator;
5. Subjects with current or past history of the following clinically significant diseases as determined by the investigator, including but not limited to diseases of the cardiovascular system, respiratory system, digestive system, urinary system, endocrine system, immune system, and nervous system (e.g., epilepsy);
6. Subjects with a current or history (within the past 3 months) of bacterial, fungal, or mycobacterial infection.;
7. Subjects with known clinically significant acute/chronic viral infections;
8. Subjects with a history of severe headache or migraine;
9. Subjects who have undergone major surgery within 6 months before drug administration, or plan to undergo surgery from the time of signing the informed consent form to 1 month after the end of the trial;
10. Subjects who have donated blood or had massive blood loss (> 450 mL) within 3 months before screening;
11. Subjects who smoked more than 5 cigarettes per day within 3 months before signing the informed consent form, or cannot refrain from using any tobacco products during the trial;
12. Subjects who consumed more than 14 units of alcohol per week within 3 months before signing the informed consent form (1 unit of alcohol ≈ 360 mL of beer, or 45 mL of spirits with 40% alcohol content, or 150 mL of wine), had a positive alcohol breath test (breath alcohol content > 0 mg/100 mL), or cannot abstain from alcohol during the trial;
13. Subjects who consumed grapefruit, grapefruit juice, chocolate, strong tea, coffee, or other beverages containing caffeine or alcohol within 72 hours before drug administration, or refuse to stop consuming the aforementioned beverages and foods during the trial;
14. Subjects who plan to engage in strenuous exercise during the trial, including contact sports or collision sports;
15. Subjects with a positive urine drug screen (for morphine, methamphetamine, ketamine, 3,4-methylenedioxymethamphetamine, or tetrahydrocannabinolic acid), or a history of drug abuse or drug use within 5 years before screening;
16. Subjects with a positive result in any of the following tests: hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (IgG), hepatitis C virus core antigen, human immunodeficiency virus (HIV) antibody, or treponema pallidum-specific antibody (TP-Ab);
17. Subjects who participated in other drug clinical trials within 3 months before screening (calculated starting from the time of the last drug administration in the previous trial);
18. Subjects who took any prescription drugs, over-the-counter drugs, or traditional Chinese herbal medicines within 30 days before screening;
19. Subjects with a positive pregnancy test result;
20. Subjects who cannot tolerate venipuncture, or have a history of hematophobia (fear of blood) or trypanophobia (fear of needles);
21. Subjects who developed an acute illness or required concomitant medication from the screening phase to before the first drug administration;
22. Subjects who received a vaccine within 2 weeks before screening, or plan to receive a vaccine during the trial;
23. Subjects deemed unsuitable for participation in this trial by the investigator.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

6

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: SAD Cohort 1; A single dose of 37.5mg BSY001 for injection or placebo administered, with 6 subjects receiving BSY001 for injection and 2 subjects receiving the placebo	Drug: BSY001 for Injection (37.5mg); A single dose of 37.5mg BSY001 for injection.; Drug: placebo-SAD; A single dose for injection.
Experimental: SAD Cohort 2; A single dose of 75 mg BSY001 for injection or placebo administered, with 6 subjects receiving BSY001 for injection and 2 subjects receiving the placebo	Drug: placebo-SAD; A single dose for injection.; Drug: BSY001 for Injection (75 mg); A single dose of 75 mg BSY001 for injection.
Experimental: SAD Cohort 3; A single dose of 150 mg BSY001 for injection or placebo administered, with 8 subjects receiving BSY001 for injection and 2 subjects receiving the placebo	Drug: placebo-SAD; A single dose for injection.; Drug: BSY001 for Injection (150 mg); A single dose of 150 mg BSY001 for injection.
Experimental: SAD Cohort 4; A single dose of 200 mg BSY001 for injection or placebo administered, with 8 subjects receiving BSY001 for injection and 2 subjects receiving the placebo	Drug: placebo-SAD; A single dose for injection.; Drug: BSY001 for Injection (200 mg); A single dose of 200 mg BSY001 for injection.
Experimental: SAD Cohort 5; A single dose of 300 mg BSY001 for injection or placebo administered, with 8 subjects receiving BSY001 for injection and 2 subjects receiving the placebo	Drug: placebo-SAD; A single dose for injection.; Drug: BSY001 for Injection (300 mg); A single dose of 300 mg BSY001 for injection.
Experimental: MAD Cohort; Administer 200 mg of BSY001 or placebo every 12 hours for 14 consecutive days. Among them, 24 subjects will receive BSY001 for injection, and the other 6 subjects will receive placebo.	Drug: BSY001 for Injection; Administer 200 mg of BSY001 every 12 hours for 14 consecutive days.; Drug: placebo-MAD; Administer placebo every 12 hours for 14 consecutive days.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety and Tolerability Parameters (SAD) - TEAE	Number and percentage of TEAE	10 days
Safety and Tolerability (SAD) - Lab tests	Lab tests (complete blood count, serum biochemistry, and coagulation parameters) at baseline compared to Lab tests 4 days and 10 days post dose.	Day 4 and day 10 post dose
Safety and Tolerability (SAD) - Physical Examination	Physical Examination at Baseline Compared to Physical Examination 4,10 Days Post Dose	Day 4 and Day 10
Safety and Tolerability Parameters (SAD) - Vital Signs	Vital signs at baseline compared to Vital signs (temperature, blood pressure, pulse, breath) day 1 pre dose, day 1, 2, 3, 4, and 10 post dose	Day 1 pre dose; Day 1, 2, 3, 4, and 10 post dose
Safety and Tolerability (SAD) - Electrocardiogram	Electrocardiogram at Baseline Compared to Electrocardiogram day 1 pre dose, 1, 4, 10 Days Post Dose	Day 1 pre dose, Day 1, 4, 10 post dose
Pharmacokinetics (MAD) - Cmax	Maximum observed plasma drug concentration.	Day 1/14 (1st/2nd dose): Within 30 min pre-dose; 0.5, 1, 2, 4, 6 ,6.5, 8, 9, 10, 12 hours post-dose. Day 4, 6, 12, 13: Within 30 min before daily first dose. 24, 48, 72, 96, 120, 144 hours after the first dose on Day 14.
Pharmacokinetics (MAD) - Cmax,ss	Steady-state peak plasma concentration	Day 1/14 (1st/2nd dose): Within 30 min pre-dose; 0.5, 1, 2, 4, 6 ,6.5, 8, 9, 10, 12 hours post-dose. Day 4, 6, 12, 13: Within 30 min before daily first dose. 24, 48, 72, 96, 120, 144 hours after the first dose on Day 14.
Pharmacokinetics (MAD) - Cmin,ss	Steady-state trough plasma concentration	Day 1/14 (1st/2nd dose): Within 30 min pre-dose; 0.5, 1, 2, 4, 6 ,6.5, 8, 9, 10, 12 hours post-dose. Day 4, 6, 12, 13: Within 30 min before daily first dose. 24, 48, 72, 96, 120, 144 hours after the first dose on Day 14.
Pharmacokinetics (MAD) - Ctrough,ss	Steady-state trough concentration	Day 1/14 (1st/2nd dose): Within 30 min pre-dose; 0.5, 1, 2, 4, 6 ,6.5, 8, 9, 10, 12 hours post-dose. Day 4, 6, 12, 13: Within 30 min before daily first dose. 24, 48, 72, 96, 120, 144 hours after the first dose on Day 14.
Pharmacokinetics (MAD) - Tmax	Time to peak concentration	Day 1/14 (1st/2nd dose): Within 30 min pre-dose; 0.5, 1, 2, 4, 6 ,6.5, 8, 9, 10, 12 hours post-dose. Day 4, 6, 12, 13: Within 30 min before daily first dose. 24, 48, 72, 96, 120, 144 hours after the first dose on Day 14.
Pharmacokinetics (MAD) - Tmax,ss	Steady-state time to peak concentration	Day 1/14 (1st/2nd dose): Within 30 min pre-dose; 0.5, 1, 2, 4, 6 ,6.5, 8, 9, 10, 12 hours post-dose. Day 4, 6, 12, 13: Within 30 min before daily first dose. 24, 48, 72, 96, 120, 144 hours after the first dose on Day 14.
Pharmacokinetics (MAD) - AUC0-t	Area under the plasma concentration-time curve from time 0 to the last measurable concentration	Day 1/14 (1st/2nd dose): Within 30 min pre-dose; 0.5, 1, 2, 4, 6 ,6.5, 8, 9, 10, 12 hours post-dose. Day 4, 6, 12, 13: Within 30 min before daily first dose. 24, 48, 72, 96, 120, 144 hours after the first dose on Day 14.
Pharmacokinetics (MAD) - AUC0-∞	Area under the plasma concentration-time curve from time 0 extrapolated to infinity	Day 1/14 (1st/2nd dose): Within 30 min pre-dose; 0.5, 1, 2, 4, 6 ,6.5, 8, 9, 10, 12 hours post-dose. Day 4, 6, 12, 13: Within 30 min before daily first dose. 24, 48, 72, 96, 120, 144 hours after the first dose on Day 14.
Pharmacokinetics (MAD) - AUC0-12h, AUC0-24h	Area under the plasma concentration-time curve from 0 to 12 hours and 0 to 24 hours	Day 1/14 (1st/2nd dose): Within 30 min pre-dose; 0.5, 1, 2, 4, 6 ,6.5, 8, 9, 10, 12 hours post-dose. Day 4, 6, 12, 13: Within 30 min before daily first dose. 24, 48, 72, 96, 120, 144 hours after the first dose on Day 14.
Pharmacokinetics (MAD) - t½,z	Terminal elimination half-life	Day 1/14 (1st/2nd dose): Within 30 min pre-dose; 0.5, 1, 2, 4, 6 ,6.5, 8, 9, 10, 12 hours post-dose. Day 4, 6, 12, 13: Within 30 min before daily first dose. 24, 48, 72, 96, 120, 144 hours after the first dose on Day 14.
Pharmacokinetics (MAD) - λz	Terminal elimination rate constant	Day 1/14 (1st/2nd dose): Within 30 min pre-dose; 0.5, 1, 2, 4, 6 ,6.5, 8, 9, 10, 12 hours post-dose. Day 4, 6, 12, 13: Within 30 min before daily first dose. 24, 48, 72, 96, 120, 144 hours after the first dose on Day 14.
Pharmacokinetics (MAD) - CLz	Clearance	Day 1/14 (1st/2nd dose): Within 30 min pre-dose; 0.5, 1, 2, 4, 6 ,6.5, 8, 9, 10, 12 hours post-dose. Day 4, 6, 12, 13: Within 30 min before daily first dose. 24, 48, 72, 96, 120, 144 hours after the first dose on Day 14.
Pharmacokinetics (MAD) - Vz	Apparent volume of distribution	Day 1/14 (1st/2nd dose): Within 30 min pre-dose; 0.5, 1, 2, 4, 6 ,6.5, 8, 9, 10, 12 hours post-dose. Day 4, 6, 12, 13: Within 30 min before daily first dose. 24, 48, 72, 96, 120, 144 hours after the first dose on Day 14.
Pharmacokinetics (MAD) - RCmax	Accumulation ratio based on Cmax	Day 1/14 (1st/2nd dose): Within 30 min pre-dose; 0.5, 1, 2, 4, 6 ,6.5, 8, 9, 10, 12 hours post-dose. Day 4, 6, 12, 13: Within 30 min before daily first dose. 24, 48, 72, 96, 120, 144 hours after the first dose on Day 14.
Pharmacokinetics (MAD) - RAUC	Accumulation ratio based on AUC	Day 1/14 (1st/2nd dose): Within 30 min pre-dose; 0.5, 1, 2, 4, 6 ,6.5, 8, 9, 10, 12 hours post-dose. Day 4, 6, 12, 13: Within 30 min before daily first dose. 24, 48, 72, 96, 120, 144 hours after the first dose on Day 14.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pharmacokinetics (SAD) - Cmax	Maximum observed plasma drug concentration before administration (within 0.5 hours); and at 0.5, 1, 2, 4, 6 (immediately post-dosing), 6.5, 8, 9, 10, 12, 16, 24, 48, and 72 hours after administration.	Before administration (within 0.5 hours); and at 0.5, 1, 2, 4, 6 (immediately post-dosing), 6.5, 8, 9, 10, 12, 16, 24, 48, and 72 hours after administration.
Pharmacokinetics (SAD) - Tmax	Time to reach Cmax before administration (within 0.5 hours); and at 0.5, 1, 2, 4, 6 (immediately post-dosing), 6.5, 8, 9, 10, 12, 16, 24, 48, and 72 hours after administration.	Before administration (within 0.5 hours); and at 0.5, 1, 2, 4, 6 (immediately post-dosing), 6.5, 8, 9, 10, 12, 16, 24, 48, and 72 hours after administration.
Pharmacokinetics (SAD) - AUC0-t	Area under the plasma concentration vs. time curve (AUC) from time 0 to the last quantifiable measurement. Samples were collected before administration (within 0.5 hours); and at 0.5, 1, 2, 4, 6 (immediately post-dosing), 6.5, 8, 9, 10, 12, 16, 24, 48, and 72 hours after administration.	Before administration (within 0.5 hours); and at 0.5, 1, 2, 4, 6 (immediately post-dosing), 6.5, 8, 9, 10, 12, 16, 24, 48, and 72 hours after administration.
Pharmacokinetics (SAD) - AUC0-∞	AUC from time 0 extrapolated to infinity	Before administration (within 0.5 hours); and at 0.5, 1, 2, 4, 6 (immediately post-dosing), 6.5, 8, 9, 10, 12, 16, 24, 48, and 72 hours after administration.
Pharmacokinetics - AUC0-12h	Area under the plasma concentration vs. time curve (AUC) from time 0 to the 12-hour time-point	Before administration (within 0.5 hours); and at 0.5, 1, 2, 4, 6 (immediately post-dosing), 6.5, 8, 9, 10, 12, 16, 24, 48, and 72 hours after administration.
Pharmacokinetics (SAD) - AUC0-24h	Area under the plasma concentration vs. time curve (AUC) from time 0 to the 24-hour time-point	Before administration (within 0.5 hours); and at 0.5, 1, 2, 4, 6 (immediately post-dosing), 6.5, 8, 9, 10, 12, 16, 24, 48, and 72 hours after administration.
Pharmacokinetics (SAD) - t1/2 z	Terminal elimination half-life	Before administration (within 0.5 hours); and at 0.5, 1, 2, 4, 6 (immediately post-dosing), 6.5, 8, 9, 10, 12, 16, 24, 48, and 72 hours after administration.
Pharmacokinetics (SAD) - λz	Terminal elimination rate constant	Before administration (within 0.5 hours); and at 0.5, 1, 2, 4, 6 (immediately post-dosing), 6.5, 8, 9, 10, 12, 16, 24, 48, and 72 hours after administration.
Pharmacokinetics (SAD) - CLz	Apparent total body clearance	Before administration (within 0.5 hours); and at 0.5, 1, 2, 4, 6 (immediately post-dosing), 6.5, 8, 9, 10, 12, 16, 24, 48, and 72 hours after administration.
Pharmacokinetics (SAD) - Vz	Apparent volume of distribution	Before administration (within 0.5 hours); and at 0.5, 1, 2, 4, 6 (immediately post-dosing), 6.5, 8, 9, 10, 12, 16, 24, 48, and 72 hours after administration.
Safety (MAD) - TEAE	Number and percentage of TEAE	20 days
Safety (MAD) - Lab tests	Lab tests (complete blood count, serum biochemistry, and coagulation parameters) at baseline compared to Lab tests at day 2~6, day 7 and day 14, day 20.	day 2~6, day 7 and day 14, day 20.
Safety (MAD) - Physical Examination	Physical Examination at Baseline Compared to Physical Examination at day 20	Day 20
Safety (MAD) - Electrocardiogram	Electrocardiogram at Baseline Compared to Electrocardiogram 1 day pre dose, day 1, 2~6, 7, 14, 20.	1 day pre dose, day 1, 2~6, 7, 14, 20.
Safety (MAD) - Vital Signs	Vital signs at baseline compared to Vital signs (temperature, blood pressure, pulse, breath) day 1 pre dose, day 1, 2~6, 7,8~13, 14, and 20	day 1 pre dose, day 1, 2~6, 7,8~13, 14, and 20

Collaborators and Investigators

• Sponsor: China National Biotec Group Company Limited
• Collaborators: Beijing Institute of Biological Products Co Ltd.; Shulan (Hangzhou) Hospital

Study record dates

Study Major Dates

• Study Start (Actual): August 28, 2025
• Primary Completion (Estimated): February 13, 2026
• Study Completion (Estimated): February 13, 2026

Study Registration Dates

• First Submitted: January 9, 2026
• First Submitted That Met QC Criteria: January 22, 2026
• First Posted (Actual): January 29, 2026

Study Record Updates

• Last Update Posted (Actual): January 29, 2026
• Last Update Submitted That Met QC Criteria: January 22, 2026
• Last Verified: January 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Infections; Virus Diseases; DNA Virus Infections; Animal Diseases; Primate Diseases; Rodent Diseases; Smallpox; Poxviridae Infections; Mpox, Monkeypox; Cowpox; Therapeutics; Drug Administration Routes; Drug Therapy; Injections
• Other Study ID Numbers: BSY001-202401

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No